Moderna (MRNA) CEO Stéphane Bancel says he wants to reset the company's cost structure after the vaccine maker forecast lower sales for 2024 and higher interest rates add pressure to the biotech industry. He recalls that the company planned to reduce production capacity due to the transition to an endemic environment, launch new products in 2024 and acquire other companies in the biotech sector, to focus on infectious diseases and cancer. 
 
(MT Newswires)

Bloomberg videos